Featured Research

from universities, journals, and other organizations

New target to treat psoriasis identified

Date:
December 5, 2013
Source:
Sanford-Burnham Medical Research Institute
Summary:
A new study identifies the BTLA inhibitory receptor as a key factor in limiting inflammatory responses, particularly in skin. The research has important implications for psoriasis drug development. By targeting the BTLA receptor, inflammatory responses can be reined to restore immune homeostasis.

Psoriasis is the most prevalent autoimmune disease in the United States.
Credit: Alejandro dans Neergaard

Sanford-Burnham scientists have identified the B and T Lymphocyte Attenuator (BTLA) inhibitory receptor as a key factor in limiting inflammatory responses, particularly in the skin. The study, published online today in Immunity, provides clarity on how T cells get fired up to protect against pathogens, and then cool down to restore immune homeostasis.

"Our study shows that BTLA expression in gamma-delta T-cells deactivates their response to immune stimuli," said Carl Ware, Ph.D., professor and director of the Infectious and Inflammatory Disease Center at Sanford-Burnham. "Gamma-delta T-cells are the first line of defense against pathogens -- and unless 'turned off', can lead to unwanted inflammation and tissue destruction."

Until now, scientists knew that gamma-delta T-cells were important for initiating inflammatory responses in the skin, but not how to turn off these potent cells.

"Now, we know that BTLA acts as a critical coordinator for turning T cells off to prevent the immune system from spinning out of control, and helping to rebalance the immune system," said Ware.

The findings could help scientists develop new treatments for inflammatory disorders by targeting BTLA to reduce inflammation, promote homeostasis, and control disease.

How BTLA is regulated

Using a combination of human cells and a mouse model of psoriasis, the research team described a new pathway that regulates BTLA expression. Ware's research showed that the "retinoid-related orphan receptor gamma-t" (ROR gamma-t) nuclear transcription factor works with interleukin (IL)-7, to coordinate the expression of BTLA, which in turn regulates gamma-delta T cell responses to inflammatory stimuli.

The study found that ROR gamma-t works to inhibit BTLA transcription, thereby limiting its availability in gamma-delta T-cells. This allows the expansion of T-cell numbers and their production of inflammatory cytokines, including IL-17 and TNF.

In contrast, IL-7 increases the availability of BTLA on the cell surface, reducing the number of active T cells and allowing BTLA to rein in the immune response.

"To be effective against pathogens, yet prevent damage from the body's own defenses, the immune system has to maintain a balance. In essence, BTLA helps control inflammatory responses by reducing the activity and numbers of active gamma-delta T cells," said Ware.

Immune mediated inflammatory diseases (IMIDs)

IMIDs are chronic, often disabling diseases caused by cytokine dysregulation and inflammation. There are over 80 types of IMIDs that target virtually any part of the body, including skin, connective tissue, and respiratory and gastrointestinal systems. Common IMIDs include Crohn's disease, ulcerative colitis, psoriasis, rheumatoid arthritis and lupus. Approximately 5-7% of Western society suffers from an IMID that requires treatment.

Current treatments for IMIDs include corticosteroids, immuno-suppressants and "biologics" that target specific immune signaling molecules. While these therapies are very effective in some patients, many patients have a poor response to these drugs.

"Understanding the mechanisms that control immune responses creates important breakthroughs for researchers developing drugs to treat these chronic diseases. If a drug can selectively activate BTLA, we put the brakes on gamma-delta T-cells and gain control of inflammation, prevent damage, and if possible, achieve long-term disease remission," said Ware.


Story Source:

The above story is based on materials provided by Sanford-Burnham Medical Research Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. Vasileios Bekiaris, John R. Šedý, Matthew G. Macauley, Antje Rhode-Kurnow, Carl F. Ware. The Inhibitory Receptor BTLA Controls γδ T Cell Homeostasis and Inflammatory Responses. Immunity, 2013; DOI: 10.1016/j.immuni.2013.10.017

Cite This Page:

Sanford-Burnham Medical Research Institute. "New target to treat psoriasis identified." ScienceDaily. ScienceDaily, 5 December 2013. <www.sciencedaily.com/releases/2013/12/131205141422.htm>.
Sanford-Burnham Medical Research Institute. (2013, December 5). New target to treat psoriasis identified. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/2013/12/131205141422.htm
Sanford-Burnham Medical Research Institute. "New target to treat psoriasis identified." ScienceDaily. www.sciencedaily.com/releases/2013/12/131205141422.htm (accessed July 31, 2014).

Share This




More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Dangerous Bacteria Kills One in Florida

Dangerous Bacteria Kills One in Florida

AP (July 31, 2014) — Sarasota County, Florida health officials have issued a warning against eating raw oysters and exposing open wounds to coastal and inland waters after a dangerous bacteria killed one person and made another sick. (July 31) Video provided by AP
Powered by NewsLook.com
Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) — Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Peace Corps Pulls Workers From W. Africa Over Ebola Fears

Peace Corps Pulls Workers From W. Africa Over Ebola Fears

Newsy (July 30, 2014) — The Peace Corps is one of several U.S.-based organizations to pull workers out of West Africa because of the Ebola outbreak. Video provided by Newsy
Powered by NewsLook.com
Weather Kills 2K A Year, But Storms Aren't The Main Offender

Weather Kills 2K A Year, But Storms Aren't The Main Offender

Newsy (July 30, 2014) — Health officials say 2,000 deaths occur each year in the U.S. due to weather, but it's excessive heat and cold that claim the most lives. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



    Save/Print:
    Share:  

    Free Subscriptions


    Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

    Get Social & Mobile


    Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

    Have Feedback?


    Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
    Mobile iPhone Android Web
    Follow Facebook Twitter Google+
    Subscribe RSS Feeds Email Newsletters
    Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins